🇺🇸 FDA
Patent

US 11542275

Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors

granted A61KA61K45/06A61P

Quick answer

US patent 11542275 (Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors) held by Aurigene Discovery Technologies Limited expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aurigene Discovery Technologies Limited
Grant date
Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K45/06, A61P, A61P29/00, A61P35/00